Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma - Takeaways - MDSpire

Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma

  • By

  • Mahir Hasan

  • Wolfram Samlowski

  • Samer Nakhle

  • May 8, 2026

  • 0 min

Share

  • 1

    Combination therapy with ipilimumab and nivolumab significantly improves survival in metastatic melanoma patients.

  • 2

    Routine monitoring revealed that 44.1% of patients developed endocrinopathy, with 18.7% specifically diagnosed with hypopituitarism.

  • 3

    The median onset time for hypopituitarism was 72.5 days, indicating a relatively early occurrence during treatment.

  • 4

    Endocrinopathy was associated with improved clinical outcomes, and prompt replacement therapy minimized hospitalizations.

  • 5

    Routine endocrine function monitoring is strongly recommended for patients receiving combination immunotherapy due to high hypopituitarism rates.

Original Source(s)

Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma

  • by Mahir Hasan, Wolfram Samlowski, Samer Nakhle

  • May 8, 2026

Related Content

Intercellular mitochondrial transfer in melanoma progression and therapeutic resistance: mechanisms and targeting potential

Matrix metalloproteinase expression in basal cell carcinoma, squamous carcinoma, and melanoma: diagnostic and prognostic potential

Unmasking the “targetless” illusion: branched clonal evolution of TERT and KIT in acral melanoma revealed by sequential multi-site biopsies- a case report